UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer

Molecular cancer research, 2017-12, Vol.15 (12), p.1764-1776

2017

Volltextzugriff (PDF)

Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV

Molecular therapy, 2015-01, Vol.23 (1), p.99-107

2015

Volltextzugriff (PDF)

Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-retargeted Oncolytic Herpes Simplex Virus

Molecular therapy, 2013-03, Vol.21 (3), p.561-569

2013

Volltextzugriff (PDF)

ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth

Oncogene, 2002-10, Vol.21 (49), p.7488-7496

2002

Volltextzugriff (PDF)

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN

Blood advances, 2019-11, Vol.3 (22), p.3503-3514

2019

Volltextzugriff (PDF)

Structure-Function Studies of the bHLH Phosphorylation Domain of TWIST1 in Prostate Cancer Cells

Neoplasia (New York, N.Y.), 2015-01, Vol.17 (1), p.16-31

2015

Volltextzugriff (PDF)

GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity

Oncogene, 2002-12, Vol.21 (57), p.8696-8704

2002

Volltextzugriff (PDF)

K13 blocks KSHV lytic replication and deregulates vIL6 and hIL6 expression: a model of lytic replication induced clonal selection in viral oncogenesis

PloS one, 2007-10, Vol.2 (10), p.e1067-e1067

2007

Volltextzugriff (PDF)

BRCA1 Interaction of Centrosomal Protein Nlp Is Required for Successful Mitotic Progression

The Journal of biological chemistry, 2009-08, Vol.284 (34), p.22970-22977

2009

Volltextzugriff (PDF)

Gadd45a contributes to p53 stabilization in response to DNA damage

Oncogene, 2003-11, Vol.22 (52), p.8536-8540

2003

Volltextzugriff (PDF)

Targeting Insulin-like Growth Factor/Insulin Receptor Signaling to Overcome JAK2 Inhibitor Persistence in Myeloproliferative Neoplasms

Blood, 2017-12, Vol.130, p.2935-2935

2017

Volltextzugriff (PDF)

SHP2 Inhibition Suppresses RAS-ERK Signaling, the Development of JAK2 Inhibitor Persistence, and MPN Development in Pre-Clinical Models of Myeloproliferative Neoplasms

Blood, 2022-11, Vol.140 (Supplement 1), p.9573-9574

2022

Volltextzugriff (PDF)

SHP2 Inhibition Enhances JAK2 Inhibitor Therapy in Preclinical Models of Myeloproliferative Neoplasms

Blood, 2023-11, Vol.142 (Supplement 1), p.4530-4530

2023

Volltextzugriff (PDF)

The Persistent Survival of MPN Cells to JAK2 Inhibition Is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies

Blood, 2018-11, Vol.132 (Supplement 1), p.3064-3064

2018

Volltextzugriff (PDF)

Corrigendum to “Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells” [Neoplasia 17 (2014) 85]

Neoplasia (New York, N.Y.), 2024-07, p.101010, Article 101010

2024

Volltextzugriff (PDF)

Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus

Advances in Virology, 2012-01, Vol.2012 (2012), p.361-370

2012

Volltextzugriff (PDF)

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms

American journal of hematology, 2024-06, Vol.99 (6), p.1040-1055

2024

Volltextzugriff (PDF)

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Blood, 2017-12, Vol.130, p.1661-1661

2017

Volltextzugriff (PDF)

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells

Oncotarget, 2015-11, Vol.6 (37), p.40141-40157

2015

Volltextzugriff (PDF)

Abstract 703: Highly selective HSV virotherapy for glioblastoma

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.703-703

2014

Volltextzugriff (PDF)

Abstract 3405: E12 and E47 are essential for TWIST1 dependent suppression of oncogene-induced senescence in NSCLC

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3405-3405

2014

Volltextzugriff (PDF)

Kaposi's Sarcoma-associated Herpesvirus (KSHV) Oncoprotein K13 Bypasses TRAFs and Directly Interacts with the IκB Kinase Complex to Selectively Activate NF-κB without JNK Activation

The Journal of biological chemistry, 2007-08, Vol.282 (34), p.24858-24865

2007

Volltextzugriff (PDF)

Abstract 4771: Identification of inhibitors of TWIST1 as a treatment for lung cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4771-4771

2014

Volltextzugriff (PDF)

ET-34HIGHLY SELECTIVE HSV VIROTHERAPY FOR TREATMENT OF GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (Suppl 5), p.v87-v87

2014

Volltextzugriff (PDF)

ET-34 HIGHLY SELECTIVE HSV VIROTHERAPY FOR TREATMENT OF GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v87-v87

2014

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(32)
Dissertationen
(1)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer

Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV

Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-retargeted Oncolytic Herpes Simplex Virus

ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN

Structure-Function Studies of the bHLH Phosphorylation Domain of TWIST1 in Prostate Cancer Cells

GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity

K13 blocks KSHV lytic replication and deregulates vIL6 and hIL6 expression: a model of lytic replication induced clonal selection in viral oncogenesis

BRCA1 Interaction of Centrosomal Protein Nlp Is Required for Successful Mitotic Progression

Gadd45a contributes to p53 stabilization in response to DNA damage

Targeting Insulin-like Growth Factor/Insulin Receptor Signaling to Overcome JAK2 Inhibitor Persistence in Myeloproliferative Neoplasms

SHP2 Inhibition Suppresses RAS-ERK Signaling, the Development of JAK2 Inhibitor Persistence, and MPN Development in Pre-Clinical Models of Myeloproliferative Neoplasms

SHP2 Inhibition Enhances JAK2 Inhibitor Therapy in Preclinical Models of Myeloproliferative Neoplasms

The Persistent Survival of MPN Cells to JAK2 Inhibition Is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies

Corrigendum to “Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells” [Neoplasia 17 (2014) 85]

Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells

Abstract 703: Highly selective HSV virotherapy for glioblastoma

Abstract 3405: E12 and E47 are essential for TWIST1 dependent suppression of oncogene-induced senescence in NSCLC

Kaposi's Sarcoma-associated Herpesvirus (KSHV) Oncoprotein K13 Bypasses TRAFs and Directly Interacts with the IκB Kinase Complex to Selectively Activate NF-κB without JNK Activation

Abstract 4771: Identification of inhibitors of TWIST1 as a treatment for lung cancer

ET-34HIGHLY SELECTIVE HSV VIROTHERAPY FOR TREATMENT OF GLIOBLASTOMA

ET-34 HIGHLY SELECTIVE HSV VIROTHERAPY FOR TREATMENT OF GLIOBLASTOMA

Suchergebnisse filtern